Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors
Background. Triple-negative breast cancer (TNBC) is a rare and aggressive breast cancer subtype. Unlike the estrogen receptor-positive subtype, whose recurrence risk can be predicted by gene expression-based signature, TNBC is more heterogeneous, with diverse drug sensitivity levels to standard regi...
Saved in:
Main Author: | Suntiparpluacha M. |
---|---|
Other Authors: | Mahidol University |
Format: | Article |
Published: |
2023
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/87745 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Update on immune checkpoint inhibitors in gynecological cancers
by: Heong, Valerie, et al.
Published: (2021) -
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
by: Dent, R.A, et al.
Published: (2020) -
Immune checkpoint inhibitor in recurrent hypermutated glioblastoma with POLE mutation
by: Sith Sathornsumetee, et al.
Published: (2022) -
PARP1PRED: A WEB SERVER FOR SCREENING THE BIOACTIVITY OF INHIBITORS AGAINST DNA REPAIR ENZYME PARP-1
by: Lerksuthirat T.
Published: (2023) -
Understanding resistance mechanisms and expanding the therapeutic utility of PARP inhibitors
by: Lim, J.S.J, et al.
Published: (2020)